The global liquid embolic market was valued at approximately $155 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 1.4%, reaching $171 million by 2032.
This report covers the global market for liquid embolics used primarily in the endovascular treatment of arteriovenous malformations (AVMs) and other vascular conditions requiring targeted vessel occlusion. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Unit demand is expected to rise gradually, supported by demographic trends and the broader adoption of minimally invasive neurovascular procedures. Growth will be more pronounced in emerging regions where access to interventional care is improving, while mature markets remain relatively stable due to saturation and the availability of alternative treatment technologies.
Ongoing pricing pressure, competitive bidding, and increasing market competition are expected to push ASPs downward over the forecast period, constraining overall market value expansion even as unit volumes grow. This dynamic characterizes a market where modest volume gains are partially offset by price erosion at the segment level.
Emerging markets represent the most meaningful growth opportunity in this segment. As access to interventional neurovascular care expands across Asia-Pacific, Latin America, and the Middle East, procedural volumes in these regions are expected to grow faster than in North America or Western Europe, where procedure adoption is more mature and market penetration is relatively stable. This geographic shift in growth contribution is expected to shape commercial priorities for market participants over the forecast period.
The penetration capabilities of non-adhesive liquid embolics have established them as the preferred treatment approach for certain AVM types. Non-adhesive formulations allow for controlled delivery and the ability to achieve greater nidus embolization through progressive small injections, pausing and resuming without the material hardening prematurely. These clinical advantages have supported market leadership for products with non-adhesive properties despite increased competitive pressure and the availability of alternative embolization approaches.
The introduction of detachable tip microcatheters has addressed one of the most significant procedural complications historically associated with liquid embolic use: catheter adherence. By allowing controlled, prolonged injection times without the risk of the catheter becoming permanently embedded in the embolic material, these devices have improved the practical safety profile of liquid embolic procedures and reduced a barrier to adoption that had limited use in some patient populations and care settings.
Johnson and Johnson held the second-leading position in the liquid embolic market in 2025 through its TruFill system. TruFill offers a cyanoacrylate-based liquid embolic for the endovascular treatment of cerebral AVMs, providing an adhesive formulation alternative for physicians who prefer this approach. The product maintains Johnson and Johnson's participation in the neurovascular embolization segment and offers a distinct clinical profile from non-adhesive systems for specific procedural scenarios.
Terumo was the third-leading competitor in the liquid embolic market in 2025. The company competes through its Precipitating Hydrophobic Injectable Liquid (PHIL) system, a non-adhesive liquid embolic that provides an alternative to Onyx for AVM embolization. PHIL's formulation delivers controlled, non-adhesive injection characteristics comparable to Onyx, giving physicians an alternative non-adhesive platform and introducing competitive pricing pressure within the non-adhesive liquid embolic category.
5 charts and 22 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
This report covers the global market for liquid embolics used primarily in the endovascular treatment of arteriovenous malformations (AVMs) and other vascular conditions requiring targeted vessel occlusion. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Unit demand is expected to rise gradually, supported by demographic trends and the broader adoption of minimally invasive neurovascular procedures. Growth will be more pronounced in emerging regions where access to interventional care is improving, while mature markets remain relatively stable due to saturation and the availability of alternative treatment technologies.
Ongoing pricing pressure, competitive bidding, and increasing market competition are expected to push ASPs downward over the forecast period, constraining overall market value expansion even as unit volumes grow. This dynamic characterizes a market where modest volume gains are partially offset by price erosion at the segment level.
Market Overview
The global liquid embolic market is a specialized segment within the neurovascular intervention space. Liquid embolics are injected into abnormal vessel networks to block blood flow, reducing the risk of hemorrhage and enabling more complete surgical or radiosurgical follow-up treatment. The market is characterized by slow, steady growth driven by gradual adoption of minimally invasive neurovascular techniques and improving access to care in emerging markets, partially offset by ASP erosion and competitive pressure from alternative vascular treatment platforms.Emerging markets represent the most meaningful growth opportunity in this segment. As access to interventional neurovascular care expands across Asia-Pacific, Latin America, and the Middle East, procedural volumes in these regions are expected to grow faster than in North America or Western Europe, where procedure adoption is more mature and market penetration is relatively stable. This geographic shift in growth contribution is expected to shape commercial priorities for market participants over the forecast period.
The penetration capabilities of non-adhesive liquid embolics have established them as the preferred treatment approach for certain AVM types. Non-adhesive formulations allow for controlled delivery and the ability to achieve greater nidus embolization through progressive small injections, pausing and resuming without the material hardening prematurely. These clinical advantages have supported market leadership for products with non-adhesive properties despite increased competitive pressure and the availability of alternative embolization approaches.
The introduction of detachable tip microcatheters has addressed one of the most significant procedural complications historically associated with liquid embolic use: catheter adherence. By allowing controlled, prolonged injection times without the risk of the catheter becoming permanently embedded in the embolic material, these devices have improved the practical safety profile of liquid embolic procedures and reduced a barrier to adoption that had limited use in some patient populations and care settings.
Market Drivers
Reduction in Catheter Adherence
Catheter adherence has historically been a significant procedural complication associated with liquid embolic use, limiting adoption and increasing procedural risk. Detachable tip microcatheters have addressed this problem by allowing slow, controlled, and prolonged injection times that ensure complete embolization while avoiding catheter entrapment. The detachable tip design allows the distal portion of the catheter to separate cleanly after injection, eliminating the need to forcefully retract an adherent catheter and reducing the risk of hemorrhage or catheter fragment migration. The development of alternative embolic liquid formulations, including combinations of n-Butyl Cyanoacrylate with Lipiodol and Iopamidol, is also expected to further reduce catheter adherence rates and widen the range of liquid embolic options available with improved procedural safety profiles.Penetration Capabilities
The penetration capability of liquid embolics, particularly non-adhesive formulations, represents a key clinical advantage over competing embolization approaches. Non-adhesive compounds can embolize a greater percentage of the nidus using progressive small injections, allowing the material to penetrate deeply and completely into the abnormal vessel network before solidifying. This approach supports more thorough AVM embolization in a single session, reducing the need for staged procedures and making liquid embolics the preferred treatment for complex cases where complete nidus occlusion is the clinical goal. The ability to pause and resume injection without premature hardening gives physicians greater control during the procedure, supporting adoption in demanding cases where precise delivery is required.Market Limiters
Safety Concerns
AVM embolization using liquid embolics carries the risk of unintentional catheter retention, which can lead to serious complications including hemorrhage, death, or migration of catheter fragments to other regions of the body. A study found the incidence of catheter retention following Onyx embolization to be approximately 3%. Regulatory and compliance concerns have also affected commercial dynamics in this segment: Medtronic's subsidiary ev3 pleaded guilty to charges related to the distribution of Onyx for unapproved indications outside the brain and in quantities exceeding those approved for intracranial use, with sales representatives having provided explicit procedural instructions for off-label applications. These safety and compliance events have contributed to heightened scrutiny around liquid embolic use, raising the requirements for physician training, procedural protocols, and regulatory oversight in affected markets.Introduction of New Technology
A range of newer embolization and neurovascular devices are entering the market and presenting growing competitive pressure for liquid embolics. While liquid embolics remain most commonly used for AVM treatment, some procedural crossover with aneurysm-focused devices exists, and alternative technologies are capturing cases at the margin of overlapping indications. Flow diverter devices such as the Pipeline embolization device are used primarily for large or giant wide-necked brain aneurysms, and their growing adoption reflects a broader trend toward dedicated device-based solutions for specific neurovascular conditions. Both Medtronic and MicroVention have pursued acquisitions of companies developing aneurysm embolization devices, signaling ongoing industry investment in platforms that may compete with or displace liquid embolics in select procedural settings.Market Coverage and Data Scope
- Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
- Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
- Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
- Data sources: Primary interviews with neurovascular device industry leaders and interventional physicians, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
- Care settings: Hospitals and neurovascular intervention centers.
Markets Covered and Segmentation
The liquid embolic market is analyzed as a unified segment, assessed by unit volume, ASP, and market value with historical and forecast data provided:
- Liquid Embolics
Competitive Analysis
Medtronic was the leader in the global liquid embolic market in 2025. The company's Onyx Liquid Embolic System (LES) is the dominant product in this segment, composed of a non-adhesive compound that forms a soft and malleable polymer within the target vessel following injection. Onyx's non-adhesive properties enable more controlled delivery, allow surgeons to achieve deeper nidus penetration through progressive small injections, and provide a longer working window compared to adhesive alternatives. Medtronic's market leadership in liquid embolics is supported by the extensive clinical evidence base built around Onyx and by the company's broader neurovascular portfolio, which spans flow diverter and aneurysm embolization platforms alongside liquid embolic products.Johnson and Johnson held the second-leading position in the liquid embolic market in 2025 through its TruFill system. TruFill offers a cyanoacrylate-based liquid embolic for the endovascular treatment of cerebral AVMs, providing an adhesive formulation alternative for physicians who prefer this approach. The product maintains Johnson and Johnson's participation in the neurovascular embolization segment and offers a distinct clinical profile from non-adhesive systems for specific procedural scenarios.
Terumo was the third-leading competitor in the liquid embolic market in 2025. The company competes through its Precipitating Hydrophobic Injectable Liquid (PHIL) system, a non-adhesive liquid embolic that provides an alternative to Onyx for AVM embolization. PHIL's formulation delivers controlled, non-adhesive injection characteristics comparable to Onyx, giving physicians an alternative non-adhesive platform and introducing competitive pricing pressure within the non-adhesive liquid embolic category.
Technology and Practice Trends
- Detachable tip microcatheters: These devices have meaningfully reduced catheter adherence complications, enabling controlled prolonged injection times and improving the practical safety profile of liquid embolic procedures in AVM treatment.
- Non-adhesive liquid formulations: Non-adhesive compounds such as Onyx and PHIL provide more controlled delivery than adhesive cyanoacrylate alternatives, supporting deeper nidus penetration and reducing the risk of premature occlusion during injection.
- Alternative embolic liquid development: New formulations such as n-Butyl Cyanoacrylate combined with Lipiodol and Iopamidol are being developed to further reduce catheter adherence rates and expand the range of available liquid embolic options.
- AVM embolization as primary indication: Liquid embolics remain the standard approach for AVM treatment, with clinical preference maintained by their penetration depth, controlled delivery characteristics, and established long-term outcomes.
- Aneurysm device competition: Flow diverters and intrasaccular devices are growing in adoption for aneurysm treatment and present competitive alternatives at the margin of indications where liquid embolics have historically played a role.
- Emerging market volume growth: Improving access to interventional neurovascular care across Asia-Pacific, Latin America, and the Middle East is expected to drive the most significant unit volume growth over the forecast period, with mature markets remaining comparatively stable.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.Deliverables
53 pages of detailed narrative analysis, tables, and figures.5 charts and 22 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
Why This Report
- Where are the largest and fastest-growing opportunities within the global liquid embolic market, and which regions are expected to contribute the most meaningful unit volume growth through 2032?
- How are detachable tip microcatheters and next-generation embolic liquid formulations improving the safety and adoption profile of liquid embolic procedures globally?
- What impact are flow diverters, intrasaccular devices, and other alternative neurovascular platforms having on liquid embolic procedure volumes and market share?
- How is pricing pressure and competitive bidding constraining market value growth even as unit volumes rise, and what are the implications for commercial planning?
- Which companies lead the market and how are their non-adhesive and adhesive product platforms differentiated for AVM and other vascular indications?
- What are the safety and regulatory dynamics shaping physician adoption, training requirements, and commercial strategy for liquid embolic products?
- What is the long-term outlook for AVM embolization as the primary indication, and how might procedural crossover with aneurysm treatment evolve over the forecast period?
- What are the key risks to growth, including ASP erosion, safety-related market headwinds, and competition from dedicated aneurysm embolization platforms?
Table of Contents
Research Methodology
Liquid Embolic Market
List of Charts
List of Figures
